Ebola vaccine memory under the microscope: how long does it last?

NCT ID NCT06100913

Ongoing Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study gives 30 healthy adults a single dose of the approved Ebola vaccine (Ervebo) and tracks their immune responses over time using blood, lymph node, and bone marrow samples. The goal is to understand how long the body 'remembers' the vaccine, which could guide future booster schedules. It is not testing the vaccine's effectiveness against Ebola, but rather the durability of immune memory.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ebola vaccine (Ervebo)
What this could lead to: If successful, this could help determine how often booster shots are needed to maintain protection against Ebola.
What could go wrong: This is a small, early-phase study focused on immune response, not on preventing disease. Results may not predict real-world protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBOLA VIRUS DISEASE

Contacts and locations

Locations

The Hope Clinic of the Emory Vaccine Center

Decatur, Georgia, 30030, United States
Washington University in St. Louis

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.